Structure via PubChem · Public domain (PubChem)
diazoxide
Sign in to saveAlso known as Proglycem®, SCH-6783, SRG-95213, Diazossido, Diazoxidum, Eudemine, Diazoxido
Diazoxide, sold under the brand name Proglycem among others, is a medication used to treat low blood sugar due to a number of specific causes. This includes islet cell tumors that cannot be removed and leucine sensitivity. It can also be used in refractory cases of sulfonylurea toxicity. It is taken by mouth.
Chemical data
- Formula
- C8H7ClN2O2S
- Molecular weight
- 230.67 g/mol
- IUPAC name
- 7-chloro-3-methyl-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide
- SMILES
- CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
- InChIKey
- GDLBFKVLRPITMI-UHFFFAOYSA-N
- XLogP
- 1.2
- Polar surface area
- 66.9 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Research
4,572 papers- Diazoxide.The New England journal of medicine · 1976
- Diazoxide.International anesthesiology clinics · 1978
- Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.The Journal of clinical endocrinology and metabolism · 2020
- Diazoxide choline (Vykat XR) for Prader-Willi syndrome-associated hyperphagia.The Medical letter on drugs and therapeutics · 2025
- Diazoxide.British medical journal · 1972
via PubMed
Wikidata facts
- Mass
- 229.992
Show 5 more facts
- chemical formula
- C₈H₇ClN₂O₂S
- World Health Organisation international non-proprietary name
- diazoxide
- canonical SMILES
- CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
- defined daily dose
- 0.3
- Commons category
- Diazoxide
via Wikidata · CC0
~3 min read
Article
4 sectionsContents
- Medical uses
- Side effects
- Research
- References
Diazoxide, sold under the brand name Proglycem among others, is a medication used to treat low blood sugar due to a number of specific causes. This includes islet cell tumors that cannot be removed and leucine sensitivity. It can also be used in refractory cases of sulfonylurea toxicity. It is taken by mouth.
Diazoxide, used as the salt diazoxide choline, and sold under the brand name Vykat XR, is used for the treatment of hyperphagia in people with Prader–Willi syndrome. It was approved for this use in the United States in March 2025.